These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 20124412)

  • 21. Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes.
    Ahrén B; Pacini G; Tura A; Foley JE; Schweizer A
    Horm Metab Res; 2007 Nov; 39(11):826-9. PubMed ID: 17992639
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients.
    Flint A; Kapitza C; Hindsberger C; Zdravkovic M
    Adv Ther; 2011 Mar; 28(3):213-26. PubMed ID: 21340616
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiopoietin-like protein 4 is differentially regulated by glucocorticoids and insulin in vitro and in vivo in healthy humans.
    van Raalte DH; Brands M; Serlie MJ; Mudde K; Stienstra R; Sauerwein HP; Kersten S; Diamant M
    Exp Clin Endocrinol Diabetes; 2012 Nov; 120(10):598-603. PubMed ID: 22972030
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduced postprandial proinsulinaemia and 32-33 split proinsulinaemia after a mixed meal in type 2 diabetic patients following sensitization to insulin with pioglitazone.
    Cooper MB; Al Majali K; Bailey CJ; Betteridge DJ
    Clin Endocrinol (Oxf); 2008 May; 68(5):738-46. PubMed ID: 17980009
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preferential stimulation of abdominal subcutaneous lipolysis after prednisolone exposure in humans.
    Gravholt CH; Dall R; Christiansen JS; Møller N; Schmitz O
    Obes Res; 2002 Aug; 10(8):774-81. PubMed ID: 12181386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimal dose and timing of insulin Aspart to mimic first phase insulin response in patients with recently onset type 2 diabetes.
    Gredal C; Rosenfalck A; Dejgaard A; Hilsted J
    Diabetes Res Clin Pract; 2008 May; 80(2):293-8. PubMed ID: 18304675
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The osteoblast: Linking glucocorticoid-induced osteoporosis and hyperglycaemia? A post-hoc analysis of a randomised clinical trial.
    van Bommel EJM; de Jongh RT; Brands M; Heijboer AC; den Heijer M; Serlie MJ; van Raalte DH
    Bone; 2018 Jul; 112():173-176. PubMed ID: 29729427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes.
    Muscelli E; Casolaro A; Gastaldelli A; Mari A; Seghieri G; Astiarraga B; Chen Y; Alba M; Holst J; Ferrannini E
    J Clin Endocrinol Metab; 2012 Aug; 97(8):2818-26. PubMed ID: 22685234
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impaired beta-cell function in human aging: response to nicotinic acid-induced insulin resistance.
    Chang AM; Smith MJ; Galecki AT; Bloem CJ; Halter JB
    J Clin Endocrinol Metab; 2006 Sep; 91(9):3303-9. PubMed ID: 16757523
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beta and alpha cell function in metabolically healthy but obese subjects: relationship with entero-insular axis.
    Calanna S; Piro S; Di Pino A; Maria Zagami R; Urbano F; Purrello F; Maria Rabuazzo A
    Obesity (Silver Spring); 2013 Feb; 21(2):320-5. PubMed ID: 23404781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects.
    Nagel JM; Tietz AB; Göke B; Parhofer KG
    Metabolism; 2006 Sep; 55(9):1149-54. PubMed ID: 16919531
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increment of serum C-peptide measured by glucagon test closely correlates with human relative beta-cell area.
    Fujita Y; Kozawa J; Iwahashi H; Yoneda S; Uno S; Yoshikawa A; Okita K; Eguchi H; Nagano H; Imagawa A; Shimomura I
    Endocr J; 2015; 62(4):329-37. PubMed ID: 25740613
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes.
    Barrington P; Chien JY; Showalter HD; Schneck K; Cui S; Tibaldi F; Ellis B; Hardy TA
    Diabetes Obes Metab; 2011 May; 13(5):426-33. PubMed ID: 21251178
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of lowering postprandial hyperglycemia on insulin secretion in older people with impaired glucose tolerance.
    Chang AM; Smith MJ; Bloem CJ; Galecki AT; Halter JB
    Am J Physiol Endocrinol Metab; 2004 Nov; 287(5):E906-11. PubMed ID: 15213063
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of incretin hormones on beta-cell function in subjects with normal or impaired glucose tolerance.
    Muscelli E; Mari A; Natali A; Astiarraga BD; Camastra S; Frascerra S; Holst JJ; Ferrannini E
    Am J Physiol Endocrinol Metab; 2006 Dec; 291(6):E1144-50. PubMed ID: 16478775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Finnish Diabetes Risk Score is associated with insulin resistance but not reduced β-cell function, by classical and model-based estimates.
    Brodovicz KG; Dekker JM; Rijkelijkhuizen JM; Rhodes T; Mari A; Alssema M; Nijpels G; Williams-Herman DE; Girman CJ
    Diabet Med; 2011 Sep; 28(9):1078-81. PubMed ID: 21843304
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study.
    Bonadonna RC; Heise T; Arbet-Engels C; Kapitza C; Avogaro A; Grimsby J; Zhi J; Grippo JF; Balena R
    J Clin Endocrinol Metab; 2010 Nov; 95(11):5028-36. PubMed ID: 20739378
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of atorvastatin (10 mg/day) on glucose metabolism in patients with the metabolic syndrome.
    Huptas S; Geiss HC; Otto C; Parhofer KG
    Am J Cardiol; 2006 Jul; 98(1):66-9. PubMed ID: 16784923
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of AZD9567 vs. prednisolone on glycaemic control in patients with type 2 diabetes mellitus: Results from a phase 2a clinical trial.
    Ambery P; Zajac G; Almquist J; Prothon S; Astbury C; Brown MN; Nemes S; Nsabimana J; Edman K; Öberg L; Lepistö M; Edenro G; Dillmann I; Mitra S; Belfield G; Keen C; Heise T
    Br J Clin Pharmacol; 2024 Aug; 90(8):1921-1931. PubMed ID: 38690606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.